January 2026
BioMed Center

The non-profit company Biomed Center Innovation is a research institute combining expertise in materials science and additive manufacturing with biological and cell-based research. Within the InkjetBioAM project, the institute focuses on inkjet-based fabrication of osteochondral scaffolds under GMP-compliant conditions, hygiene and biocompatibility.  The infrastructure includes a fully equipped cell laboratory and a lab with BSL-2 approval for bacterial and virus research, with special focus on in vitro bone tissue cultivation and bacterial barrier function assays. For advanced tissue culture, the proprietary Go>3D bioreactor system is used to enable dynamic and physiologically relevant in vitro models.

Core competencies cover 3D printing of ceramic and polymer-based materials, including ceramic additive manufacturing, materials science, and the development of medical training phantoms. Process development is combined with application-driven research to translate additive manufacturing technologies into clinical and industrial contexts.

The institute actively contributes to national and regional networks, including DIN and ISO, Medical Goes Additive, Bayern Innovativ, and Medical Valley, and collaborates closely with academic and industrial partners.

November 2025 
Infineon

 As a subsidiary of Infineon Technologies AG – a global leader with more than 57.000 employees – Infineon Austria plays a key role in shaping the future of microelectronics. With headquarters in Villach and R&D centers in Graz and Linz, Infineon Austria develops and manufactures cutting-edge power semiconductors and system solutions for automotive, industrial electronics, IoT, as well as security and RFID technologies. With around 5.900 experts across Austria, Infineon ensures technological leadership and innovation at the highest international level. 

In the Inkjet BioAM project, Infineon adapts a pre-existing microchip prototype—integrating NFC, an ARM microcontroller, FLASH memory, and a multi-channel potentiostatic interface—to the specific requirements of our use case. This includes developing dedicated firmware for sensor data acquisition, data storage, and for the secure transfer of measurement data to smartphones. 

September 2025 
University of Graz

We are the Drug Delivery and Advanced Manufacturing Group at the Institute of Pharmaceutical Sciences, University of Graz, within the Department of Pharmaceutical Technology and Biopharmacy. Our team is dedicated to designing and evaluating innovative drug delivery systems that improve therapeutic outcomes. By combining cutting-edge technology with rigorous biopharmaceutical assessment, we aim to advance the next generation of medicines for better patient care. 

We apply our expertise to the development of innovative, patient-friendly drug delivery systems. As part of the Inkjet-BioAM project, we are exploring how cutting-edge printing technologies can make treatments safer and more accessible. By investigating drug interactions with biological barriers through in vitro cell cultures and ex vivo skin studies, we provide the consortium with critical insights that help translate novel technologies into therapies that truly benefit patients. 
 

We are focusing on the biopharmaceutical testing of inkjet-printed temporary tattoos in Use Case 3. This includes in vitro studies on drug release, compatibility, and safety using advanced cell culture models, as well as ex vivo skin studies combining Franz diffusion cells with open-flow microperfusion for permeability assessments. 

July 2025 
Business Upper Austria

As the main interface between industry, science, and medicine, the Medizintechnik -Cluster (MTC) – part of Business Upper Austria, the regional government’s business agency – plays a key role in shaping the future of MedTech. The MTC unites a strong network of around 200 MedTech-specific partners, fostering collaboration, innovation, and cross-sector growth across regional, national, and international projects. 

But the impact goes far beyond: Business Upper Austria acts as the leading competence center for cross-company collaboration in Upper Austria – and well beyond. More than 2,200 companies are already working successfully within its broader networks, benefitting from tailor-made support and expert services. 

In the Inkjet BioAM project, MTC leads Work Package 8, taking charge of project marketing, public visibility, and external communication. In addition, they support the consortium with strategic communication guidance, helping all project partners bring their messages to life. 

"The aim and goal of the Medizintechnik-Cluster Upper Austria is to drive digital transformation, innovation and support promising technologies in the MedTech sector. Within the Inkjet BioAM project, it is possible to raise attention to the innovative field of 3D and bioprinting within the EU sector, and further establish this technology for manufacturers to improve the lives of EU citizens in future. Our motivation is to ensure it reaches the regional Healthcare- and MedTech sector and gains visibility as an emerging field.” – Dominik Mayrhofer, Medizintechnik-Cluster, Business Upper Austria. 

May 2025
REGEMAT 3D

Founded in 2015, REGEMAT 3D (R3D) set out to become a key player in tissue engineering and is now a global reference in the 3D bioprinting sector. Driven by innovation, R3D developed two fully customizable bioprinters and patented a bioreactor for maturing constructs targeting osteochondral defects. With a presence in over 35 countries, R3D also supplies materials and consumables for cell culture and 3D bioprinting. As a partner in the Inkjet-bioAM project, R3D brings expertise to integrate its printing tools into existing systems for inkjet printing applied to three use cases. Moreover, the project allows the validation of the BMAP® Knee bioreactor, which mimics human knee anatomy and physiology, for different applications. R3D deeply values its inclusion in this European collaboration to help shape the future of therapeutics and continue to expand its network and technology. 

March 2025
SUSS - Inkjet Printing for Personalized Medicine

SUSS is a leading manufacturer of system and process solutions for micro structuring in the semiconductor industry and related markets. The SUSS portfolio covers a comprehensive range of products and solutions for wafer bonding, photomask processing and lithography including inkjet printing. For more than ten years, the SUSS LP50 advanced research inkjet printer has promoted development and evaluation of inkjet printing processes and materials. It is widely used in medical and pharmaceutical research. However, without the necessary certifications for medical equipment, these advancements cannot be made available to the general public. As part of the inkjet-bioAM project, SUSS sees the opportunity to leverage its extensive experience in inkjet printing, adapt its solutions to regulatory requirements and develop new modules for multi-material printing to enable personalized medication.

January 2025
TIGER Coatings 

specializes in manufacturing powder coatings and inkjet inks for industrial applications. In the inkjet sector, we focus on applications where specific substrates and processes are defined, and digital printing enhances production through limitless designs, in-line decoration, variable data, etc. One example is the packaging industry, where we supply water-based inks for high-speed, single-pass printing.

As part of the Inkjet-Bio-AM project, TIGER will focus on extensive ink characterization, upscaling, and production processes. A key contribution will be investigating GMP compliance in ink production.

Our motivation in the Inkjet-bio-AM project is to support further adoption of inkjet printing in biomedical applications to improve quality of life.